The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

October 17, 2017

Farrukh Awan, MD, discusses novel agents and combinations in CLL, as well as the critical importance of FISH and IGHV testing for patient selection in this population.

October 16, 2017

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses challenges with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.

February 25, 2017

Researchers hope the acquired ibrutinib resistance mutations BTK and PLCG2 can be used as biomarkers for early intervention opportunities in patients with chronic lymphocytic leukemia.

February 24, 2017

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discuss the interest in studying venetoclax (Venclexta) in a phase II study for patients with chronic lymphocytic leukemia (CLL).

February 24, 2017

A wide-ranging clinical trial is investigating a novel method of determining treatment regimens for acute myeloid leukemia based on genomic testing for each individual patient.

February 23, 2017

Jeffrey Jones, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses a concern of venetoclax (Venclexta) in a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia (CLL).

February 09, 2017

Julia White, MD, professor of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, discusses RTOG-1119 trial for patients with breast cancer.

February 07, 2017

Jennifer Woyach, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the preliminary efficacy results of the MOR208 trial in chronic lymphocytic leukemia (CLL).

February 03, 2017

Jeffrey Jones, MD, discusses promising early data for venetoclax in chronic lymphocytic leukemia after progression on BCR-pathway inhibitors, as well as the next steps with the research.

January 27, 2017

Jennifer A. Woyach, MD, discusses the preliminary results of an ongoing phase II trial of MOR208 combination regimens in chronic lymphocytic leukemia.

January 21, 2017

Jennifer Woyach, MD, associate professor, The Ohio State University, discusses ibrutinib resistance in patients with chronic lymphocytic leukemia.

January 04, 2017

An investigation of the tyrosine kinase inhibitor lapatinib plus whole-brain radiotherapy has entered into a phase II trial in the treatment of patients with brain metastases from HER2-positive breast cancer.

December 31, 2016

Don M. Benson Jr, MD, PhD, discusses the clinical development of KIR-targeted therapies.

August 16, 2016

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the long-term outcomes associated with ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL).

May 12, 2016

David P. Carbone, MD, PhD, shares insight on the CheckMate-032 and KEYNOTE-028 trials and others that are exploring immunotherapy in patients with small cell lung cancer.

March 01, 2016

Craig Hofmeister, MD, discusses two clinical trials examining combination regimens in relapsed/refractory patients with multiple myeloma.

December 21, 2015

John C. Byrd, MD, discusses the second-generation BTK inhibitor acalabrutinib, which had a 95% response rate in patients with relapsed/refractory chronic lymphocytic leukemia.

October 20, 2015

John C. Byrd, MD, discussed what his clinical experience has revealed about the optimal use of ibrutinib and idelalisib in chronic lymphocytic leukemia, as well as unanswered questions and challenges concerning these novel agents.

July 31, 2015

John C. Byrd, MD, discusses receiving the American Society of Hematology's 2015 William Dameshek Prize for his numerous therapeutic breakthroughs in chronic lymphocytic leukemia, his impactful career, and his goals for the future.

July 30, 2015

The utilization of idelalisib increased substantially between the first and second quarters of 2015, representing promising growth in a highly competitive setting.